Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Copy Top Investors Portfolio
Crypto Technical Analysis
Chart Pattern Signal

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AZN
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
AZN
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

AZN Price Prediction Next Week

Based on the provided news and data, I'll analyze AZN's price trend and provide a forecast for next week.

Technical Analysis

The stock is currently trading at $66.60, showing a bearish trend in the short term. Key technical levels:

  • Support: $64.76 (Fibonacci S1)
  • Resistance: $67.48 (Fibonacci R1)
  • RSI(14) at 50.74 indicates neutral momentum
  • MACD at -0.18 suggests bearish momentum

Recent Key Events Impact

  1. Leadership Restructuring in China:
  • AstraZeneca has restructured its leadership following a scandal involving former president Leon Wang
  • This has led to reduced engagement from Chinese hospitals and declining sales
  • Negative impact on short-term price movement
  1. FDA Approvals :
  • Datroway approved for HR-positive, HER2-negative breast cancer treatment
  • Calquence combination therapy approved for mantle cell lymphoma
  • These approvals are positive catalysts but haven't offset China concerns
  1. Medicare Drug Price Negotiations:
  • AZN's Calquence included in the next round of Medicare price negotiations
  • Could impact future pricing and revenues
  • Adding uncertainty to medium-term outlook

Price Forecast for Next Week

Based on technical indicators and recent news:

  • Bearish Scenario (60% probability): Price likely to test Fibonacci S1 at $64.76
  • Neutral Scenario (30% probability): Consolidation between $66-67
  • Bullish Scenario (10% probability): Limited upside potential to Fibonacci R1 at $67.48

Trading Recommendation Given the current technical setup and negative news flow from China operations, recommend SELL with:

  • Entry: Current market price ($66.60)
  • Target: $64.76 (Fibonacci S1)
  • Stop-loss: $67.48 (Fibonacci R1)

The stock is likely to face continued pressure due to uncertainty around Chinese operations and potential impact from Medicare price negotiations. While new drug approvals provide some positive momentum, they are unlikely to fully offset these headwinds in the short term.

Based on the provided news and data, I'll analyze AZN's price trend and provide a forecast for next week.

Technical Analysis

The stock is currently trading at $66.60, showing a bearish trend in the short term. Key technical levels:

  • Support: $64.76 (Fibonacci S1)
  • Resistance: $67.48 (Fibonacci R1)
  • RSI(14) at 50.74 indicates neutral momentum
  • MACD at -0.18 suggests bearish momentum

Recent Key Events Impact

  1. Leadership Restructuring in China:
  • AstraZeneca has restructured its leadership following a scandal involving former president Leon Wang
  • This has led to reduced engagement from Chinese hospitals and declining sales
  • Negative impact on short-term price movement
  1. FDA Approvals :
  • Datroway approved for HR-positive, HER2-negative breast cancer treatment
  • Calquence combination therapy approved for mantle cell lymphoma
  • These approvals are positive catalysts but haven't offset China concerns
  1. Medicare Drug Price Negotiations:
  • AZN's Calquence included in the next round of Medicare price negotiations
  • Could impact future pricing and revenues
  • Adding uncertainty to medium-term outlook

Price Forecast for Next Week

Based on technical indicators and recent news:

  • Bearish Scenario (60% probability): Price likely to test Fibonacci S1 at $64.76
  • Neutral Scenario (30% probability): Consolidation between $66-67
  • Bullish Scenario (10% probability): Limited upside potential to Fibonacci R1 at $67.48

Trading Recommendation Given the current technical setup and negative news flow from China operations, recommend SELL with:

  • Entry: Current market price ($66.60)
  • Target: $64.76 (Fibonacci S1)
  • Stop-loss: $67.48 (Fibonacci R1)

The stock is likely to face continued pressure due to uncertainty around Chinese operations and potential impact from Medicare price negotiations. While new drug approvals provide some positive momentum, they are unlikely to fully offset these headwinds in the short term.

AZN Similar Chart Price Prediction

The price of AZN is predicted to go up -26.39%, based on the high correlation periods with MNST. The similarity of these two price pattern on the periods is 92.65%.

stocks logo

AZN

stocks logo

MNST

Down: -26.39%Similarity: 92.65%

AZN Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030

Year

AZN Price Forecast($)

Potential Return(%)

2025

75.000

13.210

2026

66.590

0.510

2027

89.000

34.340

2028

95.000

43.400

2029

95.000

42.130

2030

120.000

79.530

What is AZN stock price prediction 2025 ?

AZN stock is predicted to reach $75 by the end of 2025, reflecting a potential 12% upside from its current price of $66.8. This projection is based on AstraZeneca's strong pipeline in oncology and weight-loss therapies, coupled with its ambitious revenue target of $80 billion by 2030. However, risks from the ongoing investigation in China may limit short-term growth.

What is AZN stock price prediction 2026 ?

AZN's stock price is currently $66.59. Based on its diversified pipeline, strong oncology segment, and projected revenue growth, analysts estimate a potential price of $89.20 by 2026, reflecting a 34% upside. However, uncertainties in the Chinese market and regulatory risks could limit this growth.

What is AZN stock price prediction 2027 ?

AZN's stock price in 2027 is projected to reach approximately $89-$95, driven by its robust pipeline, diversified portfolio, and ambitious revenue target of $80 billion by 2030. The company's focus on oncology, rare diseases, and weight management, alongside geographical expansion, supports long-term growth. However, risks like the China investigation and competitive pressures could moderate this trajectory.

What is AZN stock price prediction 2028 ?

AZN stock is predicted to reach approximately $95 by 2028. This projection is based on AstraZeneca's strong revenue growth trajectory, driven by its oncology and biopharmaceutical segments, and its ambitious target of $80 billion in revenue by 2030. However, risks such as geopolitical challenges in China and competitive pressures in weight-loss therapies could impact this forecast.

What is AZN stock price prediction 2029 ?

AZN stock is projected to reach approximately $95 by 2029, driven by its robust pipeline in oncology, biopharmaceuticals, and rare diseases, alongside its ambitious revenue target of $80 billion by 2030. The company's strong financial growth trajectory, coupled with strategic investments in key markets like the U.S. and Spain, supports this forecast. However, risks such as geopolitical challenges in China may temper growth potential.

What is AZN stock price prediction 2030 ?

AZN stock is projected to reach approximately $120 by 2030, driven by its ambitious $80 billion revenue target and strong growth in oncology, biopharmaceuticals, and rare diseases. This forecast assumes a compound annual growth rate (CAGR) of around 10% from its current price of $66.94, supported by pipeline advancements and geographical expansion. However, risks such as regulatory challenges in China and competition in weight-loss therapies could impact this trajectory.

AZN Revenue Forecast

AZN EPS Forecast

AZN FAQs

What is bull’s view on AZN?

AstraZeneca (AZN) is currently trading at $66.26, with analysts projecting a 12-month target price of $89.20, indicating a potential upside of 35%. This bullish outlook is driven by strong revenue growth across its oncology and biopharmaceutical segments, alongside promising weight-loss drug candidates in its pipeline. However, uncertainties in China due to ongoing investigations could pose short-term risks.

What is bear's view on AZN?

AstraZeneca (AZN) stock currently faces bearish sentiment due to uncertainties in its Chinese market operations, including an ongoing investigation, which could impact sales in one of its key regions. The stock is trading at $66.26, with resistance near $67.29 and support at $64.31, reflecting limited upside in the short term. Additionally, its RSI of 47.77 suggests neutral momentum, but the lack of strong catalysts and geopolitical risks weigh on its near-term outlook.

What is AZN revenue forecast for next quarter？

The market consensus for AZN's revenue in the upcoming quarter is projected to be approximately $13.59B USD.

What is AZN eps forecast for next quarter？

The market consensus for AZN's eps in the upcoming quarter is projected to be approximately $1.04 USD.

AZN VS S&P500

The company is expanding its oncology presence with several important pipeline products. In particular, the company's EGFR drug Tagrisso looks well positioned to drive major cashflows over the next decade.

The management team is focusing the pipeline toward areas of high unmet medical need, which should increase the odds of success and bring strong pricing power for the new drugs.

AstraZeneca has a large presence in emerging markets and should benefit from these markets' fast growth prospects.

Ask Intellectia about AZN

AZN Analyst's Forecast

Matthew Weston

UBS

Strong Sell → Hold

Price Target

n/a

Upside

0%

UBS upgraded AstraZeneca to Neutral from Sell with an unchanged price target of 11,300 GBp. The firm cites the stock's 24% decline over the past three months amid China government investigations and "disappointing" data on Dato-DXd lung potential for the upgrade. While significant China uncertainty, but wholesale loss of AstraZeneca's franchise seems unlikely, the analyst tells investors in a research note.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2024 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free